These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30760837)

  • 1. DNA demethylation is associated with malignant progression of lower-grade gliomas.
    Nomura M; Saito K; Aihara K; Nagae G; Yamamoto S; Tatsuno K; Ueda H; Fukuda S; Umeda T; Tanaka S; Takayanagi S; Otani R; Nejo T; Hana T; Takahashi S; Kitagawa Y; Omata M; Higuchi F; Nakamura T; Muragaki Y; Narita Y; Nagane M; Nishikawa R; Ueki K; Saito N; Aburatani H; Mukasa A
    Sci Rep; 2019 Feb; 9(1):1903. PubMed ID: 30760837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence.
    de Souza CF; Sabedot TS; Malta TM; Stetson L; Morozova O; Sokolov A; Laird PW; Wiznerowicz M; Iavarone A; Snyder J; deCarvalho A; Sanborn Z; McDonald KL; Friedman WA; Tirapelli D; Poisson L; Mikkelsen T; Carlotti CG; Kalkanis S; Zenklusen J; Salama SR; Barnholtz-Sloan JS; Noushmehr H
    Cell Rep; 2018 Apr; 23(2):637-651. PubMed ID: 29642018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Region-specific DNA hydroxymethylation along the malignant progression of IDH-mutant gliomas.
    Hana T; Mukasa A; Nomura M; Nagae G; Yamamoto S; Tatsuno K; Ueda H; Fukuda S; Umeda T; Tanaka S; Nejo T; Kitagawa Y; Yamazawa E; Takahashi S; Koike T; Kushihara Y; Takami H; Takayanagi S; Aburatani H; Saito N
    Cancer Sci; 2024 May; 115(5):1706-1717. PubMed ID: 38433527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP.
    Moure CJ; Diplas BH; Chen LH; Yang R; Pirozzi CJ; Wang Z; Spasojevic I; Waitkus MS; He Y; Yan H
    Mol Cancer Res; 2019 Oct; 17(10):2042-2050. PubMed ID: 31292202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
    Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
    J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular subtypes of glioma identified by genome-wide methylation profiling.
    Kloosterhof NK; de Rooi JJ; Kros M; Eilers PH; Sillevis Smitt PA; van den Bent MJ; French PJ
    Genes Chromosomes Cancer; 2013 Jul; 52(7):665-74. PubMed ID: 23629961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.
    Li S; Chowdhury R; Liu F; Chou AP; Li T; Mody RR; Lou JJ; Chen W; Reiss J; Soto H; Prins R; Liau LM; Mischel PS; Nghiemphu PL; Yong WH; Cloughesy TF; Lai A
    Clin Cancer Res; 2014 Nov; 20(22):5808-22. PubMed ID: 25224277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.
    Laffaire J; Everhard S; Idbaih A; Crinière E; Marie Y; de Reyniès A; Schiappa R; Mokhtari K; Hoang-Xuan K; Sanson M; Delattre JY; Thillet J; Ducray F
    Neuro Oncol; 2011 Jan; 13(1):84-98. PubMed ID: 20926426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
    Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
    Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGFBP2 expression predicts IDH-mutant glioma patient survival.
    Huang LE; Cohen AL; Colman H; Jensen RL; Fults DW; Couldwell WT
    Oncotarget; 2017 Jan; 8(1):191-202. PubMed ID: 27852048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma.
    Glowacka WK; Jain H; Okura M; Maimaitiming A; Mamatjan Y; Nejad R; Farooq H; Taylor MD; Aldape K; Kongkham P
    Acta Neuropathol; 2018 Apr; 135(4):617-634. PubMed ID: 29428975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
    Noushmehr H; Weisenberger DJ; Diefes K; Phillips HS; Pujara K; Berman BP; Pan F; Pelloski CE; Sulman EP; Bhat KP; Verhaak RG; Hoadley KA; Hayes DN; Perou CM; Schmidt HK; Ding L; Wilson RK; Van Den Berg D; Shen H; Bengtsson H; Neuvial P; Cope LM; Buckley J; Herman JG; Baylin SB; Laird PW; Aldape K;
    Cancer Cell; 2010 May; 17(5):510-22. PubMed ID: 20399149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulator dysfunction and oncogene activation in IDH mutant gliomas.
    Flavahan WA; Drier Y; Liau BB; Gillespie SM; Venteicher AS; Stemmer-Rachamimov AO; Suvà ML; Bernstein BE
    Nature; 2016 Jan; 529(7584):110-4. PubMed ID: 26700815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
    Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
    Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
    Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T
    Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
    Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
    Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.